INSM logo

Insmed Incorporated (INSM)

$121.86

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on INSM

Market cap

$26.73B

EPS

-2.83

P/E ratio

--

Price to sales

19.31

Dividend yield

--

Beta

0.82516

Price on INSM

Previous close

$122.88

Today's open

$122.80

Day's range

$118.44 - $123.32

52 week range

$90.39 - $212.75

Profile about INSM

CEO

William H. Lewis

Employees

1664

Headquarters

Bridgewater, NJ

Exchange

Nasdaq Global Select

Shares outstanding

219380309

Issue type

Common Stock

INSM industries and sectors

Healthcare

Biotechnology & Life Sciences

News on INSM

Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead

Insmed NASDAQ: INSM expects its bronchiectasis drug BRINSUPRI to generate $1.35 billion to $1.4 billion in its first full year of launch, Chief Executive Officer Will Lewis said, as the company looks to reach more patients and expand its pipeline.

news source

MarketBeat • Nov 17, 2026

news preview

Insmed Incorporated (INSM) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Insmed Incorporated (INSM) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Nov 16, 2026

news preview

4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth

TGTX, BCRX, INSM and MDGL are expanding product sales through rising demand, broader patient access and new market opportunities.

news source

Zacks Investment Research • Nov 10, 2026

news preview

Insmed: A Blockbuster Launch, Priced Ahead Of Its Own Guidance

Insmed Incorporated is rated Hold, with a fair value of ~$99 versus a $110 share price, reflecting a blockbuster BRINSUPRI launch. INSM's valuation assumes BRINSUPRI sustains ~$75M quarterly sales growth for three years, exceeding the company's Q4 midpoint guidance. Key catalysts are Q4 2026 BRINSUPRI sales and the January 2027 FDA decision on ARIKAYCE's label expansion; either could shift the rating.

news source

Seeking Alpha • Nov 7, 2026

news preview

Insmed to Present at November and December 2026 Investor Conferences

BRIDGEWATER, N.J., Nov. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: Jefferies Global Healthcare Conference in London on Monday, November 16, 2026, at 2:00 p.m.

news source

PRNewsWire • Nov 4, 2026

news preview

INSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised Guidance

Insmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.

news source

Zacks Investment Research • Oct 30, 2026

news preview

Insmed Incorporated (INSM) Q3 2026 Earnings Call Transcript

Insmed Incorporated ( INSM ) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDT Company Participants William Lewis - President, CEO & Chairman Sara Bonstein Martina Flammer - Chief Medical Officer Conference Call Participants Yesha Patel - Evercore ISI Institutional Equities, Research Division Jessica Fye - JPMorgan Chase & Co, Research Division Faisal Khurshid - Jefferies LLC, Research Division Andrea Tan - Goldman Sachs Group, Inc., Research Division Ritu Baral - TD Cowen, Research Division Jason Zemansky - BofA Securities, Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Maxwell Skor - Morgan Stanley, Research Division Leonid Timashev - RBC Capital Markets, Research Division Olivia Brayer - Cantor Fitzgerald & Co., Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the Insmed Third Quarter 2026 Financial Results Conference Call.

news source

Seeking Alpha • Oct 31, 2026

news preview

What Insmed (INSM) Said on Its Q3 Earnings Call

Insmed NASDAQ: INSM reported third-quarter 2026 revenue growth from both of its commercial respiratory products and raised the low end of its full-year revenue guidance for BRINSUPRI and ARIKAYCE.

news source

MarketBeat • Oct 29, 2026

news preview

Insmed Reports Third-Quarter 2026 Financial Results and Provides Business Update

—Total Company Revenues of $524.4 Million for the Third Quarter of 2026— —BRINSUPRI ®  (brensocatib) Revenues of $400.1 Million for the Third Quarter of 2026, Reflecting 29% Growth Over the Second Quarter of 2026— —ARIKAYCE ® (amikacin liposome inhalation suspension) Revenues of $124.4 Million for the Third Quarter of 2026, Reflecting 9% Growth Over the Third Quarter of 2025— —Company Raises 2026 BRINSUPRI Revenue Guidance to $1.35 Billion to $1.4 Billion— —Company Raises 2026 ARIKAYCE Revenue Guidance to $460 Million to $470 Million— — Insmed Launches BRINSUPRI Tablets 25 mg (brensocatib hydrate) for the Treatment of Non-Cystic Fibrosis Bronchiectasis in Japan— BRIDGEWATER, N.J., Oct. 29, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

news source

PRNewsWire • Oct 29, 2026

news preview

Insmed (INSM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Insmed (INSM) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

news source

Zacks Investment Research • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Insmed Incorporated

Open an M1 investment account to buy and sell Insmed Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in INSM on M1